Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset

Recent media reports commented about a possible issue of the misuse of antidiabetics related to molecules promoted as a weight-loss treatment in non-obese people. We evaluated here available pharmacovigilance misuse/abuse signals related to semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiappini, Stefania, Vickers-Smith, Rachel, Harris, Daniel, Papanti Pelletier, G. Duccio, Corkery, John Martin, Guirguis, Amira, Martinotti, Giovanni, Sensi, Stefano L., Schifano, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384093/
https://www.ncbi.nlm.nih.gov/pubmed/37513906
http://dx.doi.org/10.3390/ph16070994

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384093/
https://www.ncbi.nlm.nih.gov/pubmed/37513906
http://dx.doi.org/10.3390/ph16070994

Ejemplares similares